tbuckley/cabot-search huggingface dataset:
Abstract 437: The Relation Between Cerebral Oxygenation and Blood Flow During CPR in Swine
Authors: Jeffrey R Gould, Michael Lick, Joshua W Lampe, Paul S Berger, Anja Metzger
Journal: Circulation (2019)

Introduction: The physiology underlying cerebral oxygenation and blood flow during resuscitation from cardiac arrest (CA) is poorly understood. This study examined the relation between cerebral oxygenation and blood flow during standard CPR (SCPR) and CPR with active decompression and lift (ACD) plus an impedance threshold device (ITD). Methods: Ventricular fibrillation (VF) was electrically induced in 15 domestic swine. Following 6 minutes of untreated VF, chest compressions were initiated at 100 cpm and 10% anterior-posterior distance. Depth increased to 20% anterior-posterior distance over a 2-min period, and was then maintained for 6 minutes (SCPR). ACD+ITD was performed for an additional 6 minutes at the same rate and depth as SCPR, but with 20% anterior-posterior distance of active lift. Microspheres were injected 2 minutes after the start of SCPR and ACD+ITD to measure blood flow. Cerebral oxygenation was measured using NIRS, and 8-sec averages collected 2 minutes following microsphere injection were used for comparison. Changes in oxygenation and blood flow that occurred in response to ACD+ITD relative to SCPR were analyzed using linear regression to predict oxygenation based on blood flow. Results: ACD+ITD increased blood flow in 13 animals and oxygenation in 12 animals relative to SCPR. Changes in cerebral oxygenation were directly proportional to changes in blood flow for 12 of 15 animals in response to ACD+ITD following SCPR. Cerebral blood flow explained 34% of the variance in cerebral oxygenation ( R 2 = 0.34, F (1, 13) = 6.7, P = 0.02). Conclusions: Changes in cerebral oxygenation during CA are associated with measured changes in cerebral blood flow, however 66% of the variance in cerebral oxygenation remains unexplained. Other physiological parameters should be considered to further understand how NIRS may provide clinically useful information during resuscitation.
Organisation of Sarcoma Patient Management in Reference Centers in Netsarc Network: Analysis of The Quality of Resection
Authors: S. Bonvalot, P. Meeus, E. Stoeckle, B. Bui, A. Le Cesne, N. Penel, I.L. Ray-Coquard, J. Coindre, C. Chemin, J. Blay
Journal: Annals of Oncology (2012)
64Cu-DOTA-Trastuzumab-PET Imaging in Patients with HER2-Positive Breast Cancer
Authors: K. Tamura, K. Yonemori, H. Kurihara, M. Kodaira, M. Yunokawa, C. Shimizu, M. Ando, Y. Fujiwara
Journal: Annals of Oncology (2012)
CD41は,マウス造血幹細胞で発生的に制御され,特異的に発現する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Robin Catherine, Ottersbach Katrin, Boisset Jean-Charles, Oziemlak Aneta, Dzierzak Elaine
Journal: Blood (2011)
The transcription factor T-bet is essential for the development of NKp46( ) innate lymphocytes via the Notch pathway (vol 14, pg 389, 2013)
Authors: Lucille Rankin, Joanna R Groom, Michael Chopin, Marco J Herold, Jennifer A Walker, Lisa A Mielke, Andrew Nj McKenzie, Sebastian Carotta, Stephen L Nutt, Gabrielle T Belz
Journal: Nature Immunology (2013)
BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (MCRC) In Daily Clinical Practice: Correlations with Clinical Characteristics, Prognostic and Predictive Values
Authors: Z. Saridaki, M. Tzardi, M. Sfakianaki, C. Papadaki, K. Mpananis, E. Tsakalaki, M. Trypaki, I. Messaritakis, V. Georgoulias, J. Souglakos
Journal: Annals of Oncology (2012)
Weekly Paclitaxel (PAC), Pegylated Liposomal Doxorubicin (PLD) or Topotecan (TOP) ± Bevacizumab (BEV) in Platinum (PT)-Resistant Recurrent Ovarian Cancer (OC): Analysis by Chemotherapy (CT) Cohort in the GCIG Aurelia Randomised Phase III Trial
Authors: A.M. Poveda, F. Selle, F. Hilpert, A. Reuss, A. Pasic, A. Savarese, I.B. Vergote, P. Witteveen, A. Bamias, D. Bollag, E. Pujade-Lauraine
Journal: Annals of Oncology (2012)
An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling
Authors: Juwina Wijaya, BaoHan T. Vo, Jingjing Liu, Beisi Xu, Gang Wu, Yao Wang, Junmin Peng, Jin Zhang, Laura J. Janke, Brent A. Orr, Jiyang Yu, Martine F. Roussel, John D. Schuetz
Journal: Cancer Research (2020)

Abstract Mutations in Sonic hedgehog (SHH) signaling promote aberrant proliferation and tumor growth. SHH-medulloblastoma (MB) is among the most frequent brain tumors in children less than 3 years of age. Although key components of the SHH pathway are well-known, we hypothesized that new disease-modifying targets of SHH-MB might be identified from large-scale bioinformatics and systems biology analyses. Using a data-driven systems biology approach, we built a MB-specific interactome. The ATP-binding cassette transporter ABCC4 was identified as a modulator of SHH-MB. Accordingly, increased ABCC4 expression correlated with poor overall survival in patients with SHH-MB. Knockdown of ABCC4 expression markedly blunted the constitutive activation of the SHH pathway secondary to Ptch1 or Sufu insufficiency. In human tumor cell lines, ABCC4 knockdown and inhibition reduced full-length GLI3 levels. In a clinically relevant murine SHH-MB model, targeted ablation of Abcc4 in primary tumors significantly reduced tumor burden and extended the lifespan of tumor-bearing mice. These studies reveal ABCC4 as a potent SHH pathway regulator and a new candidate to target with the potential to improve SHH-MB therapy. Significance: These findings identify ABCC4 transporter as a new target in SHH-MB, prompting the development of inhibitors or the repurporsing of existing drugs to target ABCC4.
Co-circulation of multiple enterovirus D68 subclades, including a novel B3 cluster, across Europe in a season of expected low prevalence, 2019/20
Authors: Sofie Elisabeth Midgley, Kimberley Benschop, Robert Dyrdak, Audrey Mirand, Jean-Luc Bailly, Sibylle Bierbaum, Stefan Buderus, Sindy Böttcher, Anna-Maria Eis-Hübinger, Mario Hönemann, Veronika Vorobieva Jensen, Ulla Birgitte Hartling, Cécile Henquell, Marcus Panning, Marianne Kragh Thomsen, Emma B Hodcroft, Adam Meijer
Journal: Eurosurveillance (2020)

Enterovirus D68 (EV-D68) was detected in 93 patients from five European countries between 1 January 2019 and 15 January 2020, a season with expected low circulation. Patients were primarily children (n = 67, median age: 4 years), 59 patients required hospitalisation and five had severe neurologic manifestations. Phylogenetic analysis revealed two clusters in the B3 subclade and subclade A2/D. This circulation of EV-D68 associated with neurological manifestations stresses the importance of surveillance and diagnostics beyond expected peak years.
Influence of CYP1A2, CYP3A5 and CYP2C19 Polymorphisms on Imatinib Mesylate Drug Responses in Three Major Asian Ethnic Groups and Variation of IM and Active Metabolite (M1) Trough Level Among Chronic Myeloid Leukemia Patients
Authors: K.-L. Tan, S.-H. Gan, R. Hassan, A.D. Abdullah, A. Husin, A.A. Baba, R. Ankathil
Journal: Annals of Oncology (2012)
Characteristics and Outcome of <i>AKT1</i>E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Authors: Lillian M. Smyth, Qin Zhou, Bastien Nguyen, Celeste Yu, Eva M. Lepisto, Monica Arnedos, Michael J. Hasset, Michele L. Lenoue-Newton, Natalie Blauvelt, Semih Dogan, Christine M. Micheel, Chetna Wathoo, Hugo Horlings, Jan Hudecek, Benjamin E. Gross, Ritika Kundra, Shawn M. Sweeney, JianJiong Gao, Nikolaus Schultz, Andrew Zarski, Stuart M. Gardos, Jocelyn Lee, Seth Sheffler-Collins, Ben H. Park, Charles L. Sawyers, Fabrice André, Mia Levy, Funda Meric-Bernstam, Philippe L. Bedard, Alexia Iasonos, Deborah Schrag, David M. Hyman
Journal: Cancer Discovery (2020)

AKT inhibitors have promising activity in AKT1 E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinical outcomes of patients with matched AKT1 E17K-mutant (n = 153) and AKT1-wild-type (n = 302) metastatic breast cancer. AKT1-mutant cases had similar adjusted overall survival (OS) compared with AKT1-wild-type controls (median OS, 24.1 vs. 29.9, respectively; P = 0.98). AKT1-mutant cases enjoyed longer durations on mTOR inhibitor therapy, an observation previously unrecognized in pivotal clinical trials due to the rarity of this alteration. Other baseline clinicopathologic features, as well as durations on other classes of therapy, were broadly similar. In summary, we demonstrate the feasibility of using a novel and publicly accessible clincogenomic registry to define outcomes in a rare genomically defined cancer subtype, an approach with broad applicability to precision oncology. SIGNIFICANCE: We delineate the natural history of a rare genomically distinct cancer, AKT1 E17K-mutant ER-positive breast cancer, using a publicly accessible registry of real-world patient data, thereby illustrating the potential to inform drug registration through synthetic control data.See related commentary by Castellanos and Baxi, p. 490.
TRIP8bスプライス変異体は,脳において、HCNチャンネルのゲート開閉および輸送を制御する一群の補助サブユニットを形成する | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Santoro Bina, A Piskorowski Rebecca, Pian Phillip, Hu Lei, Liu Haiying, A Siegelbaum Steven
Journal: Neuron (2009)
Government mismanaged delayed PFI hospital projects, says spending watchdog
Authors: Adrian O’Dowd
Journal: BMJ (2020)

The government has been criticised for its handling of the growing costs of two delayed private finance initiative (PFI) hospital projects in England that were run by the former company Carillion.

The Royal Liverpool University Hospital and the Midland Metropolitan Hospital, in Sandwell, missed their completion deadlines by several years and were costing an extra £616m (€720m; $800m), said the public spending watchdog the National Audit Office, in a report into the rescue of the two PFI hospital contracts that Carillion was building at the time it collapsed.1 However, much of the extra cost will not be left to the taxpayer to meet, the NAO said.

Carillion went into liquidation in January 2018 with the loss of …
Social media companies should be forced to share data for harms and benefits research, say psychiatrists
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Social media companies should be forced to hand over their data to universities for independent research into the risks and benefits of social media use, according to the Royal College of Psychiatrists.1

The college said the government’s plans to set up an online safety regulator to improve internet safety, announced last year as part of the white paper on online harms,2 should be extended to give the regulator power to compel companies to hand over their data.

They said the data would be anonymous but include the nature of content viewed, as well as the amount of …
P-0116 Preoperative Cea Level is a New Indicator of Poor Prognosis in Patients with Invasive Ductal Adenocarcinoma of Pancreas
Authors: Rintaro Koga, Akio Saiura, Junichi Arita, Ryuji Yoshioka, Nobuyuki Takemura, Yoshihiro Ono, Toshiharu Yamaguchi
Journal: Annals of Oncology (2012)
Tesetaxel: Analysis of Two Dosing Schedules (ONCE WEEKLY VS. EVERY 3 WEEKS) Using a Novel Oral Taxane
Authors: M. Beeram, K. Papadopoulos, A.W. Tolcher, D. Rasco, T. Cousin, L. Itri, A. Patnaik
Journal: Annals of Oncology (2012)
Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM)
Authors: R. Dummer, S. Goldinger, C. Turtschi, N. Eggmann, O. Michielin, L. Mitchell, L. Veronese, P.R. Hilfiker, J.D. Rinderknecht
Journal: Annals of Oncology (2012)
Evaluation of Symptom Impact of Dacomitinib (PF-00299804) Versus Erlotinib in Patients with Advanced NSCLC after Chemotherapy Failure
Authors: J. O'Connell, A. Bottomley, S.S Ramalingam, M.J. Boyer, K. Park, F. Blackhall, R. Mundayat, S.-Y. Lee, A. Campbell
Journal: Annals of Oncology (2012)
L6.3 Molecular Characterization and Pre-Screening Process in Early Drug Clinical Development of PI3K-Pathway Inhibitors
Authors: J. Rodon, R. Dienstmann, J. Cortes, C. Saura, C. Aura, J. Hernández-Losa, A. Vivancos, J. Joan, J. del Campo, E. Felip, J. Seoane, J.T. Tabernero
Journal: Annals of Oncology (2012)
P-0184 Screening Practices of Australian Men and Women Categorised As “At or Slightly Above Average Risk” of Colorectal Cancer
Authors: Driss Ait Ouakrim, Alex Boussioutas, Trevor Lockett, Louisa Flander, Louise Keogh, Ingrid Winship, Graham Giles, John Hopper, Mark Jenkins
Journal: Annals of Oncology (2012)
FSGS-Causing INF2 Mutation Impairs Cleaved INF2 N-Fragment Functions in Podocytes
Authors: Balajikarthick Subramanian, Justin Chun, Chandra Perez-Gill, Paul Yan, Isaac E. Stillman, Henry N. Higgs, Seth L. Alper, Johannes S. Schlöndorff, Martin R. Pollak
Journal: Journal of the American Society of Nephrology (2020)

Background Mutations in the gene encoding inverted formin-2 (INF2), a member of the formin family of actin regulatory proteins, are among the most common causes of autosomal dominant FSGS. INF2 is regulated by interaction between its N-terminal diaphanous inhibitory domain (DID) and its C-terminal diaphanous autoregulatory domain (DAD). INF2 also modulates activity of other formins, such as the mDIA subfamily, and promotes stable microtubule assembly. Why the disease-causing mutations are restricted to the N terminus and how they cause human disease has been unclear. Methods We examined INF2 isoforms present in podocytes and evaluated INF2 cleavage as an explanation for immunoblot findings. We evaluated the expression of INF2 N- and C-terminal fragments in human kidney disease conditions. We also investigated the localization and functions of the DID-containing N-terminal fragment in podocytes and assessed whether the FSGS-associated R218Q mutation impairs INF2 cleavage or the function of the N-fragment. Results The INF2-CAAX isoform is the predominant isoform in podocytes. INF2 is proteolytically cleaved, a process mediated by cathepsin proteases, liberating the N-terminal DID to function independently. Although the N-terminal region normally localizes to podocyte foot processes, it does not do so in the presence of FSGS-associated INF2 mutations. The C-terminal fragment localizes to the cell body irrespective of INF2 mutations. In podocytes, the N-fragment localizes to the plasma membrane, binds mDIA1, and promotes cell spreading in a cleavage-dependent way. The disease-associated R218Q mutation impairs these N-fragment functions but not INF2 cleavage. Conclusions INF2 is cleaved into an N-terminal DID–containing fragment and a C-terminal DAD–containing fragment. Cleavage allows the N-terminal fragment to function independently and helps explain the clustering of FSGS-associated mutations.
O-0027 Single Nucleotide Polymorphisms (SNPS) in the p53, SMAD7 and TGFBR1 Genes Associated with Advanced Colorectal Cancer in Caucasian Patients Compared to Healthy Controls.
Authors: Marc Pauly, Brigitte Metzger, Garry Mahon, Alain Menzel, Bernard Weber, Mario Dicato
Journal: Annals of Oncology (2012)
Strategies to achieve fairer prices for generic and biosimilar medicines
Authors: Alessandra Ferrario, Guillaume Dedet, Tifenn Humbert, Sabine Vogler, Fatima Suleman, Hanne Bak Pedersen
Journal: BMJ (2020)

Early market entry and rapid uptake of quality assured generic and biosimilars are key to improving access to medicines, say Alessandra Ferrario and colleagues
<i>Candida auris</i>Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Authors: Belinda Ostrowsky, Jane Greenko, Eleanor Adams, Monica Quinn, Brittany O’Brien, Vishnu Chaturvedi, Elizabeth Berkow, Snigdha Vallabhaneni, Kaitlin Forsberg, Sudha Chaturvedi, Emily Lutterloh, Debra Blog, Coralie Bucher, Ronald Jean Denis, Richard Erazo, Rafael Fernandez, Karen Southwick, Yan Chun Zhu
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Although rare, Candida auris resistant to all three classes of commonly used antifungal drugs was identified in three patients in New York. CDC considers C. auris an urgent threat, the highest category of concern.
O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM)
Authors: Carles Pericay, Gunnar Folprecht, Mark Saunders, Anne Thomas, Jae Kyung Roh, Rafael Lopez, Thomas Höhler, Jun Suk Kim, Chiara Zilocchi, Emmanuelle Boëlle, John Zalcberg
Journal: Annals of Oncology (2012)
P-0095 Sonic Hedgehog Paracrine Signaling Activates Pancreatic Stellate Cells to Promote The Perineural Invasion of Pancreatic Cancer in Vivo
Authors: Xuqi Li, Han Liu, Qinhong Xu, Jianjun Lei, Wanxing Duan, Qingyong Ma
Journal: Annals of Oncology (2012)
Review of the Current Status of Kras Mutation Testing in France in 2011: The Flash-Kras Study
Authors: M. Ducreux, A. Lièvre, P. Artru, M. Guiu, J. Merlin, J.C. Sabourin, J. Viguier, A. Bastie, A. Seronde, P. Laurent-Puig
Journal: Annals of Oncology (2012)
The dual systems in temporal cognition: A spatial analogy
Authors: Andrea Roselli
Journal: Behavioral and Brain Sciences (2019)

Abstract The model presented by the authors can explain an inherent contradiction in people's naïve theory of time. In this commentary I suggest a way in which another paradox of our phenomenal temporality may be addressed along these lines. In the final section, I also discuss some concerns that may arise about the clear-cut distinction between humans and non-human animals.
A Phase III Study Comparing Amrubicin and Cisplatin (AP) with Irinotecan and Cisplatin (IP) for the Treatment of Extended-Stage Small Cell Lung Cancer (ED-SCLC): JCOG0509
Authors: H. Kaneda, Y. Kotani, M. Satouchi, M. Ando, N. Yamamoto, Y. Ichinose, Y. Ohe, M. Nishio, T. Hida, K. Takeda, S. Kudoh, K. Minato, T. Shibata, T. Tamura, N. Saijo
Journal: Annals of Oncology (2012)
Rib stress injuries in the 2012–2016 (Rio) Olympiad: a cohort study of 151 Australian Rowing Team athletes for 88 773 athlete days
Authors: Rachel Harris, Larissa Trease, Kellie Wilkie, Michael Drew
Journal: British Journal of Sports Medicine (2020)

Aim To describe the demographics, frequency, location, imaging modality and clinician-identified factors of rib stress injury in a cohort of elite rowers over the Rio Olympiad (2012–2016). Methods Analysis of prospectively recorded medical records for the Australian Rowing Team in 2013–2015 and the combined Australian Rowing Team and Olympic Shadow Squad in 2016, examining all rib stress injuries. Results 19 rib stress injuries (12 reactions and 7 fractures) were identified among a cohort of 151 athletes and included 12 female and 7 male cases, 11 open weight, 8 lightweight, 12 scull and 7 sweep cases. The most common locations of injury identified by imaging, were the mid-axillary line and rib 6. Period prevalence varied from 4% to 15.4% and incidence ranged from 0.27 to 0.13 per 1000 athlete days. There were no significant differences in prevalence by sex, sweep versus scull or weight class. There was a statistically significant increase in incidence in the pre-Olympic year (2015, p&lt;0.001). MRI was the most commonly used modality for diagnosis. Stress fracture resulted in median 69 (IQR 56–157) and bone stress reaction resulted in 57 (IQR 45–78) days lost to full on water training. Conclusions In our 4-year report of rib stress injury in elite rowing athletes, period prevalence was consistent with previous reports and time lost (median ~10 weeks) was greater than previously published literature. Rib stress injury limits training and performance in elite rowers and MRI should be considered as a first line investigation.
Variation in Ultrasound Diagnostic Thresholds for Carotid Stenosis in the United States
Authors: Jesse A. Columbo, Robert M. Zwolak, Edward J. Arous, Philip P. Goodney, Michael P. Lilly, H. Gilbert Welch
Journal: Circulation (2020)

Background: Individuals with carotid stenosis enter surveillance or are considered for surgery on the basis of disease severity assessed by ultrasound. However, there is variation in the ultrasound diagnostic thresholds used to determine disease severity. Our objective was to describe this variation and its potential impact on patients. Methods: To describe the variation in carotid ultrasound diagnostic thresholds, we examined testing protocols from 338 accredited vascular testing centers in the United States. To determine the potential impact of this variation, we applied the range of thresholds to carotid ultrasound parameters from 2 groups: a population-based sample ≥65 years of age in the Cardiovascular Health Study (n=4791), and a cohort of patients who underwent surgery for asymptomatic carotid stenosis in the Vascular Quality Initiative registry (n=28 483). Results: Internal carotid artery peak systolic velocity was used by all centers to assess disease severity, with 60 distinct thresholds in use. The peak systolic velocity threshold for moderate (≥50%) stenosis ranged from 110 to 245 cm/s (median, 125; 5th and 95th percentile, 125 and 150), and the threshold for severe (≥70%) stenosis ranged from 175 to 340 cm/s (median, 230; 5th and 95th percentile, 230 and 275). In the population-based sample, the 5th percentile threshold would assign a diagnosis of moderate carotid stenosis to twice as many individuals as the 95th percentile threshold (7.9% versus 3.9%; relative risk, 2.01 [CI, 1.70–2.38]). In the surgical cohort, 1 in 10 (9.8%) patients had peak systolic velocity values that warranted the diagnosis of severe carotid stenosis at centers in the 5th percentile, but not in the 95th. Conclusions: The diagnostic threshold for carotid stenosis varies considerably. Whether or not a person is said to have moderate stenosis and enters surveillance, and whether or not they have severe stenosis and are candidates for surgery, can depend on which center performs their ultrasound.
Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial
Authors: N. Machida, S. Hironaka, K. Shinozaki, M. Sato, K. Taku, K. Watanabe, K. Amagai, T. Okuno, E. Baba, M. Goto, Y. Tsuji, S. Morita, I. Okamoto, N. Boku, I. Hyodo
Journal: Annals of Oncology (2012)